It is suggested that the mutation disrupts the tumor suppressive activity of TP53 by hindering the binding of the TP53 product to DNA (Bullock and Fersht, 2001; Saha et al., 2015; Soussi and Wiman, 2015). The gene discussed is TP53; the disease is neoplasm.